Skip to main content

Mapping from the International Classification of Diseases (ICD) 9th to 10th Revision for Research in Biologics and Biosimilars Using Administrative Healthcare Data

    Basic Details

    The Centers for Medicare and Medicaid Services (CMS) mandated the transition from ICD-9 to ICD-10 codes on October 1, 2015. Postmarketing surveillance of newly marketed drugs, including novel biologics and biosimilars, requires a robust approach to convert ICD-9 to ICD-10 codes for study variables. We examined three mapping methods for health conditions (HCs) of interest to the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) and compared their prevalence. Using CMS General Equivalence Mappings, we applied forward-backward mapping (FBM) to 108 HCs and secondary mapping (SM) and tertiary mapping (TM) to seven preselected HCs. A physician reviewed the mapped ICD-10 codes. The prevalence of the 108 HCs defined by ICD-9 versus ICD-10 codes was examined in BBCIC's distributed research network (September 1, 2012, to March 31, 2018). We visually assessed the prevalence trends of these HCs and applied a threshold of 20% level change in ICD-9 versus ICD-10 prevalence.


    Mengdong He, Adrian J. Santiago Ortiz, James Marshall, Aaron B. Mendelsohn, Jeffrey R. Curtis, Charles E. Barr, Catherine M. Lockhart, Seoyoung C. Kim